A Phase 4 interventional study of FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care and Standard of Care in Dry Eye and Cataract Surgery, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-18.
Sponsored by Alcon Research · Phase 4, Interventional, and Treatment
The purpose of this study is to evaluate the effectiveness of FID 112903 (SYSTANE ULTRA® Lubricating Drops) plus standard of care to standard of care alone, in subjects with a history of intermittent eye irritation or dryness related to environmental factors and scheduled for routine cataract surgery.
1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.
This study's enrollment of 40 is below the median of 80 across 1,155 interventional studies indexed under Cataract.
Browse Cataract studies →Alcon Research is the lead sponsor of 608 studies on the registry; 9 are open to participants now.
Of its 109 completed or terminated interventional studies of FDA-regulated products, 99 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
Other: FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care
Post Cataract Standard of Care Regimen
Other: Standard of Care
Patients will dose 4 times daily for 30 days with FID 112903 and follow routine standard of care post-operatively
Post Cataract Surgery Standard of Care
Ocular Comfort
Ocular comfort will be reported by the patient on a questionnaire
Time frame: 30 days
No study locations are listed for this record.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alcon Research